Alnylam rebuked by FDA over efficacy claims on Amvuttra website

7th May 2026 Uncategorised 0

The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.

More: Alnylam rebuked by FDA over efficacy claims on Amvuttra website
Source: fierce